Lane-Oliver Research and Design

From FBSA Wiki
Revision as of 15:22, 29 January 2022 by Greycat (talk | contribs) (→‎Regeneris)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Lane-Oliver Research and Design (LORD)
Founder: Daniel Oliver, Sera Lane
Basics
Alignment(s): Grey/Red
Motto: '
Leader(s): Sera Lane
Logo: '
Group Colours: '
Playerbase
Levels: '
Play style: '
Roleplay: Yes
Timezone(s): '
Recruiting: '
Contact: '
Think "Crey, but not."


Paragon city. Sunday: Sara Lane, COO of Lane-Oliver Research and Development, publicly responded to the untimely death of the CEO, Franklin Oliver. Mr. Oliver, aged 53, was discovered dead in his office late Friday evening. While the cause has yet to be determined, it appears to be of a heart attack.

"Franklin Oliver was not just our boss, but my friend. We combined our companies, our fortunes and our energies to create Lane-Oliver, believing that given the chance people could do great things for the good of others. And I believe our technology, biotech and medical and pharmaceutical devisions have made great strides in making that vision a reality.

"While I will miss and mourn my fellow leader and close friend, I know we will all take the opportunity to push harder and continue to make the vision of Lane-Oliver a reality in his memory. [6:05 PM] "Per our founding agreement, I will be stepping into the position of CEO for the organization, pending board approval. Meanwhile, in recognition of this great loss to our company, most of our offices will be closed for a day, with pay. Those workers who cannot be spared will get an extra day of PTO to use, and everyone will find an extra week available to them. A company memorial will be announced later."

Lane-Oliver Research and Development (Ticker: LRD) was founded in 2016 by Sera Lane and Franklin Oliver through the merger of Lane Advanced Medical Electronics (LAME) and Syntheal Bioresearch (SyB.) Through patents and projects, the company has grown from a combined worth of 1.6m USD to an annual profit of 3.78B USD last year. Subdivisions include New Reach prosthetics and biomechanics and BGN pharmaceuticals, both recent recipients of military contracts.

=====

Description

Lane-Oliver Research and Design - LORD, from here out - is actually several companies under the main administrative one.

History

Pre-merger

Syntheal Bioresarch

Daniel Oliver was an industrialist interested in "medical philantrhopy." While he had good intentions, he burned through half his fortune mismanaging businesses before his son, Franklin Oliver, took over and convinced his father to keep his hands off. Franklin Oliver was ruthless about cutting the lines that showed no promise and whittling the company down to its core, which he renamed Syntheal Bioresearch (SyB.)

Lane Advanced Medical Electronics

2016: Merger and founding of Lane-Oliver

Current day

Organization

Lane-Oliver (LORD)

Regeneris

Regeneris is currently the most exciting research division. Not only are they assisting in general medical tech, finding ways to help heal faster from wounds and researching into combating diseases like multiple sclerosis and several forms of cancer, but they've been seeing success in their stated aim of "bringing the high success, zero rejection world of cloned replacement organs down to a price where everyone can afford it," even donating their product in some cases.

Those cases tend to be high-profile, of course - or, if it's promising but not on the news, well, that's what the media relations branch is for.

Regeneris has recently had its facilities hit by the terrorist group known as the Ballroom, who claim they're creating and harvesting full human clones for organs. This, of course, they vehemently deny, citing both ethical and technical grounds as reasons they avoid that very thing. The truth? Who knows. They have a lot of labs. But so far nobody's had to make excuses for them.

Children of Tomorrow

This is the specialized reproductive health and fertility branch of Regeneris.

New Reach prosthetics

BGN Pharmaceuticals